S&P 500
7,516.60
+0.45%
Dow Jones
52,923.60
+0.01%
Nasdaq 100
29,706.80
+1.19%
Russell 2000
3,007.21
+0.49%
FTSE 100
10,654.20
-0.33%
Nikkei 225
69,824.80
+2.22%
Beam Therapeutics

Beam Therapeutics (BEAM) Q1 2026 Earnings

Reported May 7, 2026 at 7:06 AM ET · SEC Source

Q1 26 EPS

$-0.91

BEAT +10.06%

Est. $-1.01

Q1 26 Revenue

$31.7M

BEAT +159.70%

Est. $12.2M

vs S&P Since Q1 26

+9.3%

BEATING MARKET

BEAM +11.2% vs S&P +1.8%

Market Reaction

Did BEAM Beat Earnings? Q1 2026 Results

Beam Therapeutics delivered a standout first quarter for fiscal 2026, beating Wall Street estimates on both the top and bottom lines as collaboration activity drove revenue far beyond expectations. The gene-editing company posted revenue of $31.74 mi… Read more Beam Therapeutics delivered a standout first quarter for fiscal 2026, beating Wall Street estimates on both the top and bottom lines as collaboration activity drove revenue far beyond expectations. The gene-editing company posted revenue of $31.74 million, a 324.9% increase from the year-ago quarter and well ahead of the $12.22 million consensus, while its loss per share of $0.91 came in 10.06% better than the $1.01 estimate. The primary driver was robust license and collaboration revenue, which surged from $7.47 million a year ago as pipeline partnerships gained momentum. The net loss narrowed to $94.32 million from $108.33 million in the prior-year period, even as R&D spending climbed to $104.52 million to support advancing clinical programs, most notably BEAM-302 in alpha-1 antitrypsin deficiency, where the company selected a 60 mg optimal dose and now plans to pursue an accelerated FDA approval pathway with a pivotal cohort launch expected in the second half of 2026. With $1.21 billion in cash and a BLA submission for risto-cel targeted as early as year-end 2026, Beam's management sees its runway extending into mid-2029.

Key Takeaways

  • • Revenue increase driven by license and collaboration activity
  • • Operating loss improvement year-over-year despite higher R&D and G&A expenses
  • • Other income contributed $12.9 million including interest income and fair value adjustments

BEAM Forward Guidance & Outlook

Beam expects to initiate the BEAM-302 pivotal cohort in the second half of 2026, pursuing an accelerated approval pathway based on FDA feedback, with approximately 50 additional patients with AATD-associated lung disease. A BLA submission for risto-cel in sickle cell disease is expected as early as year-end 2026. An IND application for BEAM-304 in PKU is anticipated in 2026. Initial clinical data from BEAM-301 in GSDIa are expected in 2026. The Phase 1 trial of BEAM-103 is expected to complete dosing in the first half of 2026. Cash, cash equivalents and marketable securities of $1.2 billion, along with an anticipated additional $100 million from the Sixth Street facility, are expected to fund operating plans into mid-2029, through the anticipated launch of risto-cel, execution of the BEAM-302 pivotal development plan, and clinical proof of concept for BEAM-304.

24/7 Wall St

BEAM YoY Financials

Q1 2026 vs Q1 2025, source: SEC Filings

“The first quarter of 2026 was a defining period for Beam, marked by meaningful clinical advances across our portfolio and key steps toward becoming a commercial-stage company. The updated topline data from BEAM-302 – including robust increases in total AAT and a well-tolerated safety profile – give us high confidence in the 60 mg optimal biological dose and a clear path to initiating the pivotal cohort in the second half of this year.”

— John Evans, Q1 2026 Earnings Press Release

Back to BEAM Stock Page